52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.
- DOI
- 10.1111/jdv.70710
- Published
- 2026 Sep 2
- Container
- Journal of the European Academy of Dermatology and Venereology : JEADV
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/jdv.70710,
title = {52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.},
author = {Zhao Y and Gooderham M and Yang B and Wu J and Wu L and Loo WJ and Toth D and Sauder M and Li J and Chen A and Tao X and Lu J and Song Z and Han J and Li H and Li Y and Wang H and Zhang J},
year = {2026},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
doi = {10.1111/jdv.70710},
url = {https://doi.org/10.1111/jdv.70710}
}RIS
TY - JOUR TI - 52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial. AU - Zhao Y AU - Gooderham M AU - Yang B AU - Wu J AU - Wu L AU - Loo WJ AU - Toth D AU - Sauder M AU - Li J AU - Chen A AU - Tao X AU - Lu J AU - Song Z AU - Han J AU - Li H AU - Li Y AU - Wang H AU - Zhang J PY - 2026 JO - Journal of the European Academy of Dermatology and Venereology : JEADV DO - 10.1111/jdv.70710 UR - https://doi.org/10.1111/jdv.70710 ER -
APA
Y, Z., M, G., B, Y., J, W., L, W., WJ, L., D, T., M, S., J, L., A, C., X, T., J, L., Z, S., J, H., H, L., Y, L., H, W., & J, Z. (2026). 52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70710
Source records
- pubmed · retrieved 2026-09-27T01:09:50.772Z
- europe-pmc · retrieved 2026-09-27T01:09:50.796Z